Apoptosis pathways as promising targets for skin cancer therapy

British Journal of Dermatology

Volumn 156, Issue SUPPL. 3, 2007, Pages 18-24

  Eberle, J ^a   Fecker, L F ^a   Forschner, T ^a   Ulrich, C ^a   Rowert Huber J ^a   Stockfleth, E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Bcl 2; COX 2; Skin cancer; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DEATH RECEPTOR; DICLOFENAC; GENDICINE; I KAPPA B; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; OBLIMERSEN; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACTINIC KERATOSIS; APOPTOSIS; BREAST CANCER; CANCER THERAPY; DOWN REGULATION; DRUG EFFICACY; HUMAN; IMMUNITY; PRIORITY JOURNAL; REVIEW; SKIN CANCER; TUMOR RESISTANCE; ULTRAVIOLET RADIATION; UPREGULATION;

APOPTOSIS; CELL COMMUNICATION; CELL PROLIFERATION; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; SKIN NEOPLASMS;

EID: 34247385565     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07855.x     Document Type: Review

References (61)

1. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001 63 : 8 18.
2. Seiberg M. Keratinocyte-melanocyte interactions during melanosome transfer. Pigment Cell Res 2001 14 : 236 42.
3. Perry PK, Silverberg NB. Cutaneous malignancy in albinism. Cutis 2001 67 : 427 30.
4. Daya-Grosjean L, Sarasin A. The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. Mutat Res 2005 571 : 43 56.
5. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005 24 : 2899 908.
6. Wu CC, Shete S, Amos CI et al. Joint Effects of Germ-Line p53 Mutation and Sex on Cancer Risk in Li-Fraumeni Syndrome. Cancer Res 2006 66 : 8287 92.
7. Bocchia M, Bronte V, Colombo Mp et al. Antitumor vaccination: where we stand. Haematologica 2000 85 : 1172 206.
8. Nakachi K, Hayashi T, Imai K et al. Perspectives on cancer immuno-epidemiology. Cancer Sci 2004 95 : 921 9.
9. Ulrich C, Schmook T, Sachse MM et al. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 2004 30 : 622 7.
10. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972 26 : 239 57.
11. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006 12 : 440 50.
12. Hofseth LJ, Hussain SP, Harris CC. P53: 25 years after its discovery. Trends Pharmacol Sci 2004 25 : 177 81.
13. Daniel PT, Schulze-Osthoff K, Belka C et al. Guardians of cell death: the Bcl-2 family proteins. Essays Biochem 2003 39 : 73 88.
14. Er E, Oliver L, Cartron PF et al. Mitochondria as the target of the pro-apoptotic protein Bax. Biochim Biophys Acta 2006 1757 : 1301 11.
15. Shi Y. Mechanical aspects of apoptosome assembly. Curr Opin Cell Biol 2006 18 : 677 84.
16. Los M, Stroh C, Janicke RU et al. Caspases: more than just killers? Trends Immunol 2001 22 : 31 4.
17. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002 20 : 323 70.
18. Daniel PT, Wieder T, Sturm I et al. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001 15 : 1022 32.
19. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003 10 : 26 35.
20. Engels IH, Totzke G, Fischer U et al. Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner. Mol Cell Biol 2005 7 : 2808 18.
21. Sheikh MS, Fornace AJ Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000 14 : 1509 13.
22. Tomasetti M, Andera L, Alleva R et al. Alpha-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: implication for sensitisation of resistant cancer cells to TRAIL apoptosis. FEBS Lett 2006 580 : 1925 31.
23. Ward MW, Rehm M, Duessmann H et al. Real time single cell analysis of Bid cleavage and Bid translocation during caspase-dependent and neuronal caspase-independent apoptosis. J Biol Chem 2006 281 : 5837 44.
24. Fischer U, Janicke RU, Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 2003 10 : 76 100.
25. Graziani G, Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005 52 : 109 18.
26. Lu H, Hou Q, Zhao T et al. Granzyme M directly cleaves inhibitor of caspase-activated DNase (CAD) to unleash CAD leading to DNA fragmentation. J Immunol 2006 177 : 1171 8.
27. Bolshakov S, Walker CM, Strom SS et al. P53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res 2003 9 : 228 34.
28. Queille S, Luron L, Spatz A et al. Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV specific tandem CC to TT mutations of the p53 gene. Carcinogenesis 2007 28 : 724 31.
29. Blagosklonny MV. P53:an ubiquitous target of anticancer drugs. Int J Cancer 2002 98 : 161 6.
30. Zoi-Toli O, Vermeer MH, De Vries E et al. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 2000 143 : 313 9.
31. Kurbanov BM, Geilen CC, Fecker LF et al. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol 2005 125 : 1010 9.
32. Mathas S, Lietz A, Anagnostopoulos I et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004 199 : 1041 52.
33. Raisova M, Hossini AM, Eberle J et al. The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 2001 117 : 333 40.
34. Nachmias B, Ashhab Y, Ben Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 2004 14 : 231 43.
35. Dolcet X, Llobet D, Pallares J et al. NF-kB in development and progression of human cancer. Virchows Arch 2005 446 : 475 82.
36. Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ 2005 12 : 942 61.
37. Fensterle J. A trip through the signaling pathways of melanoma. Ein Streifzug durch die (Signal-)Wege des malignen Melanoms. J Dtsch Dermatol Ges 2006 4 : 205 17.
38. Jansen B, Schlagbauer-Wadl H, Brown BD et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998 4 : 232 4.
39. Klasa RJ, Gillum AM, Klem RE et al. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002 12 : 193 213.
40. Yamanaka K, Rocchi P, Miyake H et al. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU Int 2006 97 : 1300 8.
41. Oppermann M, Geilen CC, Fecker LF et al. Caspase-independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk / Bik. Oncogene 2005 24 : 7369 80.
42. Hossini AM, Geilen CC, Fecker LF et al. A novel Bcl-x splice product, Bcl-xAK, triggers apoptosis in human melanoma cells without BH3 domain. Oncogene 2006 25 : 2160 9.
43. Voorhees PM, Dees EC, O'Neil B et al. The proteasome as a target for cancer therapy. Clin Cancer Res 2003 9 : 6316 25.
44. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005 5 : 749 59.
45. Richardson PG, Briemberg H, Jagannath S et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006 24 : 3113 20.
46. Eberle J, Fecker LF, Hossini AM et al. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene 2003 22 : 9131 41.
47. Fecker LF, Geilen CC, Hossini AM et al. Selective induction of apoptosis in melanoma cells by tyrosinase promoter-controlled CD95 ligand overexpression. J Invest Dermatol 2005 124 : 221 8.
48. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003 10 : 66 75.
49. Yagita H, Takeda K, Hayakawa Y et al. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004 95 : 777 83.
50. Walczak H, Miller RE, Ariail K et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999 5 : 157 63.
51. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2005 62 : 165 86.
52. Vulfovich M, Saba N. Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda. Curr Opin Mol Ther 2005 7 : 502 10.
53. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005 16 : 1016 27.
54. Cristofanilli M, Krishnamurthy S, Guerra L et al. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer 2006 107 : 935 44.
55. Shimada H, Matsubara H, Shiratori T et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci 2006 97 : 554 61.
56. Stockfleth E, Ulrich C, Hauschild A et al. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol 2002 12 : 569 72.
57. Ulrich C, Busch JO, Meyer T et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol 2006 155 : 451 4.
58. Schon M, Bong AB, Drewniok C et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003 95 : 1138 49.
59. Schon MP, Wienrich BG, Drewniok C et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004 122 : 1266 76.
60. Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 1999 128 : 1121 32.
61. Lee JT Jr. McCubrey JA. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 2002 16 : 486 507.